SPECIALTY QUANTITY LIMIT PROGRAM

COSENTYX (secukinumab)

PROGRAM DESCRIPTION Ι.

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Cosentyx (secukinumab): 150 mg pen or syringe	1 pen/syringe per 28 days	5 pens/syringes per 35 days	 PsA/AS: Loading doses (optional): 150 mg at weeks 0, 1, 2, 3, 4 Maintenance dose: 150 mg every 4 weeks
Cosentyx (secukinumab): 300 mg dose carton containing (2) 150 mg pens or (2) 150 mg syringes	1 dose carton per 28 days	5 dose cartons per 35 days	 Plaque psoriasis, with or without coexistent psoriatic arthritis: Loading doses: 300 mg at weeks 0, 1, 2, 3, 4 Maintenance dose: 300 mg every 4 weeks (150 mg every 4 weeks may be acceptable)

Abbreviations: RA = rheumatoid arthritis; PsA = psoriatic arthritis; AS = ankylosing

*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCE

1. Cosentyx [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2018.

Specialty Quantity Limit Cosentyx 1737-H P2019

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

